Latest Newsletter, page-3

"In 2018 my lab was working on STING. Noxopharm contacted me to see if I would be interested in conducting research on idronoxil, the active ingredient of Veyonda®. The rationale at the time was that idronoxil would activate the STING pathway, which is involved in anti-tumour immunity. We discovered that idronoxil was a strong inhibitor of STING signalling in late October 2019. This was a key breakthrough. I knew this was the exact opposite of what we had set out to demonstrate for Noxopharm, but I saw the potential of this discovery since it made idronoxil the first human-ready inhibitor of STING signalling."

Think that one through for a minute.